Eupraxia Pharmaceuticals Inc. (EPRX) vs Lexeo Therapeutics, Inc. Common Stock (LXEO)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and Lexeo Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.75HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
LXEO
Lexeo Therapeutics, Inc. Common Stock
$3.19HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Total return — EPRX vs LXEO
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)LXEO -73.7% (-48.8%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
EPRX LXEO
EPRX vs LXEO: by the numbers
- •EPRX is the larger company ($259M vs $250M market cap).
Metrics side by side
Valuation
| Metric | EPRX | LXEO |
|---|---|---|
| P/B ratio | 2.55 | 1.07 |
Profitability
| Metric | EPRX | LXEO |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -38.33% | -37.12% |
| ROIC | -43.56% | -39.76% |
Go deeper
Dig into the metrics
Eupraxia Pharmaceuticals ROELexeo Therapeutics, Inc. Common Stock ROEEupraxia Pharmaceuticals operating marginLexeo Therapeutics, Inc. Common Stock operating marginEupraxia Pharmaceuticals revenue growthLexeo Therapeutics, Inc. Common Stock revenue growthEupraxia Pharmaceuticals free cash flowLexeo Therapeutics, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.